Company profile · Biotech & medical
Formosa Pharmaceuticals
台新藥股份有限公司 · 6838
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Formosa Pharmaceuticals is a clinical stage biopharmaceutical company focusing on ophthalmology and oncology.[1]
The company develops a pipeline consisting of 505(b)(2), biosimilars, and new chemical entities.[2]
It utilizes its proprietary APNT nanoparticle formulation platform to improve pharmacokinetics and bioavailability for drug candidates.[1]
Its flagship asset, APP13007, has been approved by the US FDA for the treatment of inflammation and pain following ocular surgery.[3]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$0m | – | – |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$1m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Formosa Pharmaceuticals, Inc. |
|---|---|
| Chinese name | 台新藥股份有限公司 |
| Stock code | 6838 (TWSE) |
| Industry | Biotech & medical |
| Founded | 06 Dec 2010 |
| Listed | 13 Aug 2024 |
| Paid-in capital | NT$1.5bn |
| Chairman | 程正禹 |
| President | 許力克 |
| Headquarters | 8F-6, No. 57, Fuxing N. Rd., Taipei City |
| Website | https://www.formosapharma.com |
| Official business description | 新藥研發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Home - Formosa Pharmaceuticals, Inc. · website · retrieved 04 Nov 2026
- MOPS 公司基本資料 台新藥股份有限公司 · mops · retrieved 04 Nov 2026
- Company Introduction - Formosa Pharmaceuticals, Inc. · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list